Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone

NCT00680992 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00680992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00680992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
September 9, 2008
Completion date
May 17, 2018
Enrollment
535 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

benign giant cell tumors, cancer, giant cell tumor of bone, giant cell tumors